These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 4653961)

  • 1. Effect of amantadine on the urinary excretion of some monoamines and metabolites in normal and Parkinsonian subjects.
    Jones DG; Turnbull MJ; Lenman JA; Robertson MA
    J Neurol Sci; 1972 Nov; 17(3):245-53. PubMed ID: 4653961
    [No Abstract]   [Full Text] [Related]  

  • 2. Proceedings: Effect of amantadine on the urinary excretion of some monoamines and metabolites in normal and parkinsonian subjects.
    Jones DG; Lenman JA; Robertson MA; Turnbull MJ
    Br J Pharmacol; 1972 Feb; 44(2):386P-387P. PubMed ID: 4668639
    [No Abstract]   [Full Text] [Related]  

  • 3. [Catecholamine excretion and treatment of parkinsonism with midantan].
    Kandel' EI; Iadgarov IS
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1976 Sep; 76(9):1323-6. PubMed ID: 1015136
    [No Abstract]   [Full Text] [Related]  

  • 4. Responses of the urinary excretion of homovanillic acid and of 5-hydroxy-indol-acetic acid to treatment with L-dopa and amantadine.
    Molnár G; Fodor A
    Ther Hung; 1973; 21(1):35-40. PubMed ID: 4792890
    [No Abstract]   [Full Text] [Related]  

  • 5. [The effect of alpha-DOPA on the dynamics of urinary excretion of DOPA, catecholamines and their metabolites in healthy subjects and in patients with parkinsonism].
    Matlina ESh; Kandel' EI; Vasil'ev VN; Iadgarov IS; Bol'shakova TD
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1973; 73(2):205-9. PubMed ID: 4743269
    [No Abstract]   [Full Text] [Related]  

  • 6. The biochemistry of catecholamines in relation to Parkinson's disease.
    Hinterberger H
    Aust N Z J Med; 1971 May; 1():Suppl 1:14-8. PubMed ID: 5292808
    [No Abstract]   [Full Text] [Related]  

  • 7. Urinary excretion of some monoamines and metabolites in Huntington's chorea.
    McNamee B; Kelvin AS; Turnbull MJ
    Scott Med J; 1971 May; 16(5):247-9. PubMed ID: 4253483
    [No Abstract]   [Full Text] [Related]  

  • 8. Urinary monoamine metabolite excretion in disorders of movement. Effects of amantadine and levodopa.
    Lenman JA; Turnbull MJ; Reid A; Fleming AM
    J Neurol Sci; 1977 Jun; 32(2):219-25. PubMed ID: 874521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Excretion of L-dopa and its metabolites in urine of Parkinson's disease patients receiving L-dopa therapy.
    Routh JI; Bannow RE; Fincham RW; Stoll JL
    Clin Chem; 1971 Sep; 17(9):867-71. PubMed ID: 5571485
    [No Abstract]   [Full Text] [Related]  

  • 10. [Modifications of catecholamine metabolism under the effect of a decarboxylase inhibitor associated with L-dopa and desipramine in patients with depressive and parkinsonian syndromes].
    Geissbuhler F; Bartholini G; Gaillard JM; Tissot R
    Encephale; 1971; 60(3):189-209. PubMed ID: 5119348
    [No Abstract]   [Full Text] [Related]  

  • 11. Development of a screening test for L-dopa and its metabolites in urine.
    Routh JI; Bannow RE
    Clin Chem; 1971 Sep; 17(9):872-4. PubMed ID: 5571486
    [No Abstract]   [Full Text] [Related]  

  • 12. Urinary excretion of monoamines and metabolites in patients dependent on and withdrawn from barbiturates.
    Turnbull MJ; Ballinger BR
    Psychopharmacologia; 1973 May; 30(2):103-8. PubMed ID: 4711367
    [No Abstract]   [Full Text] [Related]  

  • 13. Urinary excretion of dopamine and homovanillic acid during L-dopa treatment of Parkinson's disease.
    Streifler M; Vardi Y; Kesten M; Oberman Z; Herzberg M
    Isr J Med Sci; 1972 May; 81(5):597-601. PubMed ID: 5042950
    [No Abstract]   [Full Text] [Related]  

  • 14. Catecholamine metabolism during oral administration of levodopa.
    Hinterberger H; Andrews CJ
    Arch Neurol; 1972 Mar; 26(3):245-52. PubMed ID: 5061285
    [No Abstract]   [Full Text] [Related]  

  • 15. Excretion of catecholamines and tryptophan derivatives in schizophrenia.
    Mileikovskii YA
    Neurosci Behav Physiol; 1979; 9(4):325-8. PubMed ID: 158714
    [No Abstract]   [Full Text] [Related]  

  • 16. Studies on the metabolism and excretion of L-3,4-dihydroxyphenylalanine (L-DOPA) in human beings by gas chromatography.
    Imai K; Sugiura M; Kubo H; Tamura Z; Oya K
    Chem Pharm Bull (Tokyo); 1972 Apr; 20(4):759-64. PubMed ID: 5045616
    [No Abstract]   [Full Text] [Related]  

  • 17. Treatment of parkinsonism by amantadine and levodopa.
    Mawdsley C; Williams IR; Pullar IA; Davidson DL; Kinloch NE
    Clin Pharmacol Ther; 1972; 13(4):575-83. PubMed ID: 4557584
    [No Abstract]   [Full Text] [Related]  

  • 18. Metabolism of L-dihydroxyphenylalanine by patients with Parkinson's disease.
    Tyce GM; Muenter MD; Owen CA
    Mayo Clin Proc; 1970 Sep; 45(9):645-56. PubMed ID: 5311767
    [No Abstract]   [Full Text] [Related]  

  • 19. The effect of methyldopa on the excretion of catecholamines in patients with extrapyramidal disorders.
    Metzel A; Holldorf A; Umbach W
    Confin Neurol; 1967; 29(2):78-80. PubMed ID: 5591949
    [No Abstract]   [Full Text] [Related]  

  • 20. Treatment of Parkinson's disease with amantadine and L-Dopa.
    Rinne UK; Sonninen V; Siirtola T
    Eur Neurol; 1972; 7(4):228-40. PubMed ID: 4556618
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.